Otaka A, Mitsuyama E, Kinoshita T, Tamamura H, Fujii N
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
J Org Chem. 2000 Aug 11;65(16):4888-99. doi: 10.1021/jo000169v.
Stereoselective syntheses of all four stereoisomers of CF(2)-substituted nonhydrolyzable phosphothreonine derivatives (33, 39, and their enantiomers) and their incorporation into peptides are described herein. Key to the synthesis of these amino acids was construction of secondary phosphate-mimicking difluoromethylphosphonate units along with generation of two stereocenters. The former was achieved using a Cu(I)-mediated cross-coupling reaction of BrZnCF(2)P(O)(OEt)(2) (8) and beta-iodo-alpha,beta-unsaturated ester 12, with stereochemistry of both alpha- and beta-stereocenters being established using bornane-10,2-sultam as a chiral auxiliary. Diastereoselective hydrogenation of a chiral alpha,beta-unsaturated acylsultam (for the beta-center) (e.g., 16a) and subsequent stereoselective bromination (for the alpha-center of the threo derivative) or amination (for the alpha-center of erythro (allo) derivative) were utilized. Transesterification of the bromide to the benzyl ester followed by azide displacement of the halogen, then reduction of the resulting azide, followed by Boc-protection and finally removal of the benzyl group, afforded protected both L- and D-phosphothreonine mimetics (39 and its enantiomer). On the other hand, protected both L- and D-allo-phosphothreonine mimetics (33 and its enantiomer) were synthesized via transesterification of the above-mentioned amination product, followed by hydrogenolytic removal of the benzyl group. Key to utilization of these amino acid analogues in peptide synthesis was removal of ethyl protection from the difluoromethylphosphonate moiety. A two-step deprotection methodology, consisting of a combination of a first-step reagent [0.3 M BSTFA-TBAI in CH(2)Cl(2), BF(3).Et(2)O] followed by a second-step reagent [1 M TMSOTf-thioanisole in TFA, m-cresol, EDT] was developed for use in solid-phase protocols. A 12-residue Cdc (cell division cycle) 2-peptide 41, possessing two nonhydrolyzable phosphoamino acid mimetics (F(2)Pmab 6 and F(2)Pmp 4), was subjected to this deprotection procedure and was obtained in 25% yield based on the protected resin. The present synthetic method affords nonhydrolyzable phosphoamino acid mimetics-containing peptides in high yield without accompanying side reactions.
本文描述了CF(2)取代的不可水解磷酸苏氨酸衍生物(33、39及其对映体)的所有四种立体异构体的立体选择性合成及其掺入肽中的过程。这些氨基酸合成的关键在于构建模拟二级磷酸的二氟甲基膦酸酯单元以及生成两个立体中心。前者通过BrZnCF(2)P(O)(OEt)(2)(8)与β-碘-α,β-不饱和酯12的Cu(I)介导的交叉偶联反应实现,同时使用冰片-10,2-磺内酰胺作为手性助剂来确定α-和β-立体中心的立体化学。利用手性α,β-不饱和酰基磺内酰胺(用于β-中心)(例如16a)的非对映选择性氢化以及随后的立体选择性溴化(用于苏型衍生物的α-中心)或胺化(用于赤型(别)衍生物的α-中心)。将溴化物酯交换为苄酯,然后用叠氮基取代卤素,接着还原所得叠氮化物,再进行Boc保护,最后除去苄基,得到受保护的L-和D-磷酸苏氨酸模拟物(39及其对映体)。另一方面,通过上述胺化产物的酯交换,然后氢解脱去苄基,合成了受保护的L-和D-别-磷酸苏氨酸模拟物(33及其对映体)。在肽合成中使用这些氨基酸类似物的关键在于从二氟甲基膦酸酯部分除去乙基保护基。开发了一种两步脱保护方法,第一步试剂为[0.3 M BSTFA-TBAI于CH(2)Cl(2)中,BF(3).Et(2)O],第二步试剂为[1 M TMSOTf-苯甲硫醚于TFA、间甲酚、EDT中],用于固相合成方案。一个含有两个不可水解磷酸氨基酸模拟物(F(2)Pmab 6和F(2)Pmp 4)的12个残基的细胞分裂周期蛋白2肽41,经过此脱保护过程,基于受保护树脂,以25%的产率得到。本合成方法能高产率地得到含不可水解磷酸氨基酸模拟物的肽,且无伴随的副反应。